Michel De Wilde holds a Ph.D. in biochemistry from the Free University of Brussels and has a long and successful career in vaccine research and development. He currently consults for the vaccine community. He is member of the Boards of VBI Vaccines, Inc., and of the Infectious Disease Research Institute.
From 2001-2013, De Wilde was senior vice president of research & development, at Sanofi Pasteur where he drove the development and licensure of a number of products. Also, Sanofi’s Dengue vaccine was developed under his supervision. De Wilde was also instrumental in driving the acquisition and integration of two biotech companies: Acambis and VaxDesign.
From 1978 till 2000, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines), where he played a key role in the development of several new vaccines, most notably the recombinant Hepatitis B vaccine, as well as GSK’s Malaria vaccine candidate.